Brain, Behavior, & the Environment Program, Department of Environmental Health Sciences, Robert Stempel College of Public Health & Social Work, Florida International University, Miami, FL 33199, United States of America.
Department of Anthropology and Brain Health Research Institute, Kent State University, Kent, OH 44242, United States of America.
Neurobiol Dis. 2021 Oct;158:105467. doi: 10.1016/j.nbd.2021.105467. Epub 2021 Aug 4.
Inherited autosomal recessive mutations of the manganese (Mn) transporter gene SLC39A14 in humans, results in elevated blood and brain Mn concentrations and childhood-onset dystonia-parkinsonism. The pathophysiology of this disease is unknown, but the nigrostriatal dopaminergic system of the basal ganglia has been implicated. Here, we describe pathophysiological studies in Slc39a14-knockout (KO) mice as a preclinical model of dystonia-parkinsonism in SLC39A14 mutation carriers. Blood and brain metal concentrations in Slc39a14-KO mice exhibited a pattern similar to the human disease with highly elevated Mn concentrations. We observed an early-onset backward-walking behavior at postnatal day (PN) 21 which was also noted in PN60 Slc39a14-KO mice as well as dystonia-like movements. Locomotor activity and motor coordination were also impaired in Slc39a14-KO relative to wildtype (WT) mice. From a neurochemical perspective, striatal dopamine (DA) and metabolite concentrations and their ratio in Slc39a14-KO mice did not differ from WT. Striatal tyrosine hydroxylase (TH) immunohistochemistry did not change in Slc39a14-KO mice relative to WT. Unbiased stereological cell quantification of TH-positive and Nissl-stained estimated neuron number, neuron density, and soma volume in the substantia nigra pars compacta (SNc) was the same in Slc39a14-KO mice as in WT. However, we measured a marked inhibition (85-90%) of potassium-stimulated DA release in the striatum of Slc39a14-KO mice relative to WT. Our findings indicate that the dystonia-parkinsonism observed in this genetic animal model of the human disease is associated with a dysfunctional but structurally intact nigrostriatal dopaminergic system. The presynaptic deficit in DA release is unlikely to explain the totality of the behavioral phenotype and points to the involvement of other neuronal systems and brain regions in the pathophysiology of the disease.
人类 SLC39A14 锰(Mn)转运体基因的常染色体隐性遗传突变导致血液和大脑 Mn 浓度升高,并伴有儿童期发病的肌张力障碍-帕金森病。该疾病的病理生理学尚不清楚,但基底神经节的黑质纹状体多巴胺能系统已被牵连在内。在这里,我们描述了 Slc39a14 敲除(KO)小鼠的病理生理学研究,作为 SLC39A14 突变携带者中肌张力障碍-帕金森病的临床前模型。Slc39a14-KO 小鼠的血液和大脑金属浓度表现出与人类疾病相似的模式,Mn 浓度极高。我们在出生后第 21 天(PN)观察到早发性后退行走行为,在 PN60 Slc39a14-KO 小鼠中也观察到类似的肌张力障碍样运动。与野生型(WT)小鼠相比,Slc39a14-KO 小鼠的运动活动和运动协调能力也受到损害。从神经化学的角度来看,纹状体多巴胺(DA)及其代谢物浓度及其比值在 Slc39a14-KO 小鼠中与 WT 小鼠没有差异。Slc39a14-KO 小鼠的纹状体酪氨酸羟化酶(TH)免疫组织化学也没有改变。Slc39a14-KO 小鼠的黑质致密部(SNc)TH 阳性和尼氏染色估计神经元数量、神经元密度和体体积的无偏立体学细胞计数与 WT 小鼠相同。然而,我们测量到 Slc39a14-KO 小鼠纹状体中钾刺激的 DA 释放明显抑制(85-90%),与 WT 相比。我们的发现表明,在人类疾病的这种遗传动物模型中观察到的肌张力障碍-帕金森病与功能失调但结构完整的黑质纹状体多巴胺能系统有关。DA 释放的突触前缺陷不太可能解释行为表型的全部内容,并指出其他神经元系统和脑区参与了疾病的病理生理学。